Takeda recalls Natpara but warns patients not to abruptly stop treatment 

Takeda is voluntarily recalling all dose forms of its hypoparathyroidism drug Natpara from the U.S. market because they may contain rubber particles, but the drugmaker is warning patients they must follow precise measures when they quit taking the drug. (Pixabay)

Takeda’s been looking for a buyer for Natpara to provide some debt relief, but it has just run into some complicating circumstances. It is having to recall the drug from the market, a move it says may be very challenging for patients.

Takeda today announced it was voluntarily recalling all doses of the injected drug for hypoparathyroidism in the U.S. because there was a chance of small rubber particles shedding into the injectors. 

But the Japanese drugmaker was adamant that patients mustn’t stop the treatment abruptly because of the danger of a sudden drop in blood calcium levels. Instead, patients must have their doctor replace the drug with supplements and carefully monitor their calcium levels with blood tests.


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

RELATED: Takeda sells Shire's Xiidra, transfers 400 staffers to Novartis in $3.4B deal

“It is critically important that patients contact their prescribing healthcare provider to discuss their individual treatment plan and ensure close supervision including frequent monitoring of blood calcium levels and close titration of active vitamin D and calcium supplements upon stopping Natpara to avoid low blood calcium (hypocalcemia),” the company said.

The particles are coming from the rubber covering, or septum, in the injection cartridge. The company said that when the septum is repeatedly punctured during the 14-day treatment period, it is possible that small rubber fragments may get into the cartridge. 

Takeda said it is working with the FDA to resolve the manufacturing issues that have resulted in the recall and to resume production and supply of the drug as quickly as possible. 

RELATED: Takeda scouts buyers for Latin America business, a deal that could fetch $1B: report

The difficulty is that there is no alternative treatment for some patients. Natpara, a recombinant human protein, is the only drug approved in the U.S. for adults with the sometimes fatal chronic hypoparathyroidism for whom standard therapy alone is not working.  

Takeda said it also is working with drug regulators in other countries where Natpara is approved, but that the drug is not being recalled in those markets at this point. 

The supply interruption comes even as Takeda reportedly was looking to sell the drug as a way to improve its balance sheet after its $58 billion buyout of Shire last year. The deal was opposed by many investors because of the debt Takeda had to take on to make the buy. 

Novartis provided Takeda some relief when it bought the Shire dry-eye drug Xiidra in a deal that ultimately could be worth $5.3 billion. The Swiss drugmaker also took on 400 ex-Shire employees to help it market Xiidra and the rest of its growing ophthalmic portfolio. 

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.